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S u m m a r y  
 
Improper expression of cell cycle regulators is 
characteristic for most cancer cells. Cyclins are a group of 
proteins, with concentration changing in time, which control 
progression through each phase of the cell cycle. Maximum 
cyclin A expression falls inside S and at the beginning of M 
phase. In the S phase cyclin A is responsible for a proper run 
of the replication process, and together with cyclin B 
conditions transition into the M phase. Arsenic trioxide 
(ATO) is an efficient drug used in acute promyelocytic 
leukemia (AML). Numerous reports point that arsenic 
trioxide can be applied in therapy of other types of cancer as 
well. The purpose of these study was to evaluate influence of 
arsenic trioxide on the expression and localization of cyclin 
A in Jurkat cell line. Additionally, we determined the effect 
of ATO on morphology and ultrastructure of the Jurkat cells. 
In order to reach this aim we applied classic light, 
florescence and electron transmission microscopy. A dose-
dependent decrease in the percentage of viable cells was 
observed. Morphological and ultrastructural alterations 
suggest that apoptosis and autophagy are induced by ATO. 
Image-based cytometry showed high extent of necrotic cells 
after ATO treatment. A decrease in cyclin A level was 




S t r e s z c z e n i e  
 
Nieprawidłowa ekspresja regulatorów cyklu komórko-
wego jest cechą charakterystyczną komórek nowotwo-
rowych. Cykliny stanowią grupę białek, których stężenie 
zmienia się w czasie, kontrolują one prawidłowy przebieg 
cyklu komórkowego. Cyklina A stanowi białko, którego 
maksimum ekspresji przypada na fazy S i G2 i jest ona 
odpowiedzialna za właściwy przebieg procesu replikacji  
w fazie S, a wraz z cykliną B warunkuje przejście komórki 
do fazy M. Zastosowany w badaniu trójtlenek arsenu (ATO) 
stanowi skuteczny lek w terapii ostrej białaczki promielo-
cytowej. Liczne doniesienia wskazują, że może być on także 
wykorzystywany w terapii innych typów nowotworów.  
Celem niniejszej pracy było określenie wpływu 
trójtlenku arsenu na ekspresję cykliny A w linii komórkowej 
Jurkat. Poziom ekspresji i lokalizację cykliny A określono za 
pomocą klasycznego mikroskopu fluorescencyjnego. 
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Ponadto zbadano wpływ trójtlenku arsenu na morfologię  
i ultrastrukturę komórek Jurkat przy użyciu mikroskopu 
świetlnego i transmisyjnego mikroskopu elektronowego. 
Stwiedzono zależny od zastosowanej dawki cytostatyku 
spadek odsetka żywych komórek. Zaobserwowane zmiany 
morfologiczne i ultrastruturalne sugerują indukcję apoptozy 
i autofagii pod wpływem trójtlenku arsenu. Badania za 
pomocą cytometru obrazowego wykazały wysoki odsetek 
komórek nekrotycznych po traktowaniu trójtlenkiem arsenu. 
Stwierdzono spadek ekspresji cykliny A wraz z rosnącą 
dawką trójtlenku arsenu, jednocześnie nie została zauważona 
zmiana lokalizacji cykliny z jądrowej na cytoplazmatyczną.  
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Arsenic trioxide (ATO) has been used for medical 
purposes for thousands of years. Today, application of 
arsenic trioxide includes treatment of acute 
promyelocytic leukemia (APL), in which it is used as a 
first line drug alone and in combination therapy
 
[1]. 
Arsenic trioxide may induce apoptosis through  several 
pathways, and the mechanism of its action differs 
depending on cell and tumor type. In APL cells arsenic 
trioxide leads to degradation of the PML-RARα fusion 
protein and restores proper cell differentiation. In other 
cells ATO can induce apoptosis through the intrinsic 
and extrinsic pathway, arrest cells in G0/G1 and G2/M 
phases and trigger autophagy. Moreover, arsenic 
trioxide can inhibit angiogenesis
 
[2]. In the current 
study we investigated the influence of ATO on the 
expression of one of the cell cycle regulators - cyclin A 
in the Jurkat cells, which are widely used as in vitro 
model of T-cell acute lymphoblastic leukemia (T-
ALL). Each cell cycle is divided into two essential 
events: replication of DNA in S phase and cell 
division, finally resulting in two daughter cells in M 
phase. Progression through each phase is driven by 
CDKs, the activity of which depends on their partners 
– cyclins. The amount of CDKs do not change in time, 
but concentration of cyclins fluctuates, which allows 
activation of appropriate CDKs in accurate and ordered 
manner
 
[3]. Two types of cyclin A are present in higher 
eukaryotes. Expression of cyclin A1 is limited to germ 
cells, whereas cyclin A2 (hereafter referred to as cyclin 
A) is present in somatic and germ cells. Cyclin A starts 
to accumulate from the S phase and is degraded in 
prometaphase. Cyclin A binds and activates both 
CDK-2 and CDK-1 and controls replication process in 
S phase, playing at the same time essential role in M 
phase entry. Moreover, cyclin A participates in 
chromatin condensation and nuclear envelope 
breakdown
 
[4-5]. Improper expression of cyclins may 
cause excessive cell growth and malignant 





[6]. Some studies suggest the 
involvement of cyclin A in apoptotic pathways. One of 
the important factors determining cyclin A function is 
the localization of the protein. Some studies showed 
link between CDK2 localization and its role in 
apoptosis and suggested that cyclin A/CDK2 
complexes play a twofold role as pro-survival and pro-
apoptotic protein
 
[7-8]. In our study we investigated 
how arsenic trioxide affects expression and localization 
of cyclin A in Jurkat cell line. Additionally, we 
evaluate morphological and ultrastructural changes in 




Cell culture and treatment 
Jurkat human lymphoblastoid cell line was obtained 
from the Department of Dermatology and Sexually 
Transmitted Diseases, Nicolaus Copernicus University 
in Toruń Ludwik Rydygier Collegium Medicum in 
Bydgoszcz, Poland). The cells were cultured in 
monolayers at 37
o
C in a humidified CO2 incubator 
(5% CO2 in air) in RPMI 1640 (Lonza) with the 
addition of 10% FBS (fetal bovine serum; Sigma-
Aldrich) and 50 mg/ml of gentamycin (Sigma-
Aldrich). Arsenic trioxide (Trisenox, Teva Pharma 
B.V.) was diluted in sterile water and added to cell 
cultures at 1, 3, and 5 µM for 24 h. 10µl cell 
suspension was added to an equal volume of diluted 
Trypan Blue stain (Sigma-Aldrich). The number of 
stained cells and total number of cells was counted 
using Bürker counting chamber. 
 
Light microscopy 
For the morphological analysis, the Jurkat cells 
were fixed in 4% paraformaldehyde and then incubated 
with 0.1 M glycine solution. The cells were stained 
with Mayer’s hematoxylin, rinsed under running tap 
water and dehydrated in a graded series of alcohols and 
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xylenes. The preparations were observed using an 
Eclipse E800 microscope (Nikon) with NIS-Elements 
image analysis system and CCD camera (DS-5Mc-U1; 
Nikon). 
 
Transmission electron microscopy 
Conventional electron microscopy was used to 
visualize Jurkat cells morphology at the ultrastructural 
level. The cells were fixed in 3.6% glutaraldehyde (pH 
7.2, Polysciences, Warrington, PA, USA) (30 min, 
RT). After washing in 0.1 M sodium cacodylate buffer 
(pH 7.4; Roth, Karlsruhe, Germany), the cells were 
postfixed in 1% buffered OsO4 (Serva, Heidelberg, 
Germany) for 1 h, dehydrated in ethanol (30–90%) and 
acetone (90-100%) and embedded in Epon E812 (Roth, 
Karlsruhe, Germany) polymerized 24 h at 37°C and 7 
days in 65°C. Semithin sections were stained with 1% 
toluidine blue and used for targeting the cells. Ultrathin 
sections (40 nm thick) were cut with a diamond knife 
(Diatome, Bienne, Switzerland) by Reichert Om U3 
ultramicrotome (Leica Microsystems, Vienna, Austria) 
on copper grids (Sigma- Aldrich; St. Louis, MO, USA) 
and stained with 1% uranyl acetate (Ted Pella, Inc., 
Redding, CA, USA) and lead citrate (Ted Pella, Inc., 
Redding, CA, USA). The material was examined using 
a transmission electron microscope JEM 100 CX 
(JEOL, Tokyo, Japan) operating at 60 kV on IMAGO – 
EM23 film (NDT System, Warsaw, Poland). 
 
Fluorescence microscopy 
Cells were fixed with 4% paraformaldehyde (pH 
7.4) for 15 min, at 4˚C, washed twice with PBS and 
collected directly onto microscopical slides using a 
cytocentrifuge (Megafuge1, OR, Heraeus, Sepatech). 
Cells on slides were incubated in permeabilization 
solution (0.1% Triton X-100 in PBS) and blocked with 
1% BSA (Gibco). After permeabilization, cells were 
incubated with mouse monoclonal anti-cyclin A 
antibody (Sigma) for 60 min at room temperature, 
washed three times with PBS and incubated with Alexa 
Fluor 488 goat antimouse IgG antibody (Invitrogen) 
for 45 min, at room temperature. After incubation, cells 
were washed with PBS and mounted in Aqua 
Poly/Mount (Polysciences, Inc.). Nuclear staining was 
performed with DAPI (Sigma). Both cyclin A and 
DNA staining was examined with an Eclipse E800 




Annexin V/propidium iodide (PI) binding assay 
Apoptosis was determined by staining cells with 
Tali® Apoptosis kit - Annexin V Alexa Fluor® 488 
and Propidium Iodide (Invitrogen) was used according 
to the manufacturer's instructions. In short, after the 
arsenic trioxide treatment, the cells were collected 
from 6-well plates using trypsin-EDTA solution, 
centrifuged at 300×g for 8 min, resuspended in ABB 
(annexin binding buffer) and incubated with Annexin 
V Alexa Fluor® 488 at room temperature in the dark 
for 20 minutes. Following the centrifugation at 300 × g 
for 5 min, the cells were again resuspended in ABB 
and incubated with propidium iodide at room 
temperature in the dark for 5 minutes. The cells were 
analyzed using a Tali® Image-Based Cytometer 
(Invitrogen). The data were quantified by FCS Express 
Research Edition software (version 4.03; De Novo 
Software, New Jersey, NJ,  USA) and expressed as the 
percentage of cells in each population (viable Annexin 
V-/PI-; early apoptotic Annexin V+/PI-; late apoptotic 




The non-parametric Mann-Whitney U test was 
performed to compare the differences between 
untreated and treated cells. The results were considered 
statistically significant at p<0.05. The GraphPad Prism 





Trypan blue staining demonstrated that treatment of 
Jurkat cells for 24 h with increasing concentrations of 
ATO up to 5 µM, decreased cell viability in a dose-
dependent manner. As shown in figure 1 the mean 
number of viable cells was 95% in the control group, 
88% after 1 µM, 79% after 3 µM and 61% following 5 
µM dose (Fig. 1). The changes in morphology of 
Jurkat cells after ATO treatment were examined under 
a light microscope. The control cells exhibited a typical 
round or kidney-shape morphology and maintained 
their adherence to each other (fig. 2A). Following the 
treatment with 1 µM ATO, some cells kept proper 
shape but some were characterized by increased size 
and altered nucleus (fig. 2B). Further progression in 
doses caused more severe morphological changes. In 
cells treated with 3 µM lobed nuclei were observed. 
The treatment with arsenic trioxide at concentration of 
5 µM resulted in the loss of round shape. Cells were 
irregular, enlarged or shrunken, some giant cells with 
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large fragmented nucleus were also observed. In 
shrunken cells we noticed condensation of chromatin. 
At the highest dose arsenic trioxide caused progressive 
degradation as well as extensive vacuolization of the 
cell (fig. 2C and 2D). 
 
 
Fig. 1. The effect of arsenic trioxide (ATO) on cell survival 
Cells were incubated with the indicated concentrations of 
ATO. Asterisks denote statistical significance as compared to 
control cells (p<0.05). Results are representative of five 
independent experiments. 
Ryc. 1. Wpływ trójtlenku arsenu na przeżycie komórek 
Komórki były inkubowane z dodatkiem trójtlenku arsenu w 
podanych stężeniach. Gwiazdki wskazują istotne 
statystycznie różnice w stosunku do komórek kontrolnych 





Fig. 2. The effect of ATO on the morphology of Jurkat cells  
A: control cells, B: cells treated with 1 μM ATO, C: cells 
treated with 3 μM ATO, D: cells treated with 5 μM ATO. 
Bar 50 μm. Enlarged cells or cells irregular in shape (I), cells 
with lobate nucleus (II) and shrunken cells (III) were 
reported.  
Ryc. 2. Wpływ trójtlenku arsenu na morfologię komórek 
Jurkat 
A: komórki kontrolne, B: komórki traktowane 1 μM ATO,  
C: komórki traktowane 3 μM ATO, D: komórki traktowane  
5 μM ATO. Bar 50 μm. Widoczne powiększone komórki lub 
komórki o nieregularnym kształcie (I), komórki z jądrem 
płatowatym (II) oraz komórki obkurczone (III). 
 
Electron microscopic studies confirmed the above-
described observations. The cells treated with 1, 3, 5 
µM ATO showed augmented increase in ultrastructure 
alterations as the ATO dose increased. The control 
cells were regular in shape, had nucleus with distinct 
nucleoli and proper organelles such as the 
mitochondria, rough endoplasmic reticulum with 
visible ribosomes and Golgi apparatus (fig. 3A). The 
cells treated with 1 µM  ATO maintained their regular 
shape, but alterations in the nucleus were observed. 
Moreover, we noticed swollen mitochondria and 
dilation of endoplasmic reticulum (fig.3B). The 
incubation with arsenic trioxide at the concentration of 
3 µM resulted in loss of cell shape and cell membrane 
rupture. The nuclear volume increased slightly and 
condensed chromatin was visible (fig. 3C). The highest 
dose of ATO (5 µM) caused more evident but similar 
changes in the majority of cells including 
disintegration of nucleus, and appearance of lysosome-
like structures. Additionally, a considerable 




Fig. 3. The ultrastructure of Jurkat cells treated with (ATO) 
A: control cells, B: Cells treated with 1 µM ATO, C: Cells 
treated with 3 µM ATO, D: Cells treated with 5 µM ATO. 
Bar 5 µm. Swollen mitochondria (I), chromatin condensation 
(II) and cytoplasm vacuolization (III) were observed.  
Ryc. 3. Wpływ ATO na ultrastukturę komórek Jurkat 
A: komórki kontrolne, B: komórki traktowane 1μM ATO, C: 
komórki traktowane 3 μM ATO, D: komórki traktowane  
5 μM ATO. Bar 5 μm. Strzałkami zaznaczono obrzmiałe 
mitochondria (I), kondensację chromatyny (II) i wakuolizację 
cytoplazmy (III). 
 
The fluorescence staining was applied to evaluate 
changes in cyclin A expression and localization. 
Arsenic trioxide strongly suppressed cyclin A 
expression in the Jurkat cell line. There was  
a statistically significant difference in the number of 
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cyclin A-positive cells between the control group and 
ATO-treated cells. Moreover, there was no visible 
change in cyclin A localization. The protein was 
localized mainly in the nucleus in all groups; however, 
after ATO treatment, a small amount of cyclin A in the 
cytoplasm was found (Fig. 4). Next we determined the 
apoptotic effects of arsenic trioxide in Jurkat cells. The 
applied doses were highly toxic for the cells, and 
induced dose-dependent necrotic death. Only small 




Fig. 4. Fluorescence microscopic examination of cyclin A 
localization in Jurkat cells treated with ATO 
The cells were treated with 1, 3 and 5 µM ATO and 
immunolabeled for the presence of cyclin A (A,B,C,D). Cell 
nuclei were stained with DAPI (A’,B’,C’D’). Arrows point 
cells with cytoplasmic expression of cyclin A. Bar 50 μm. 
Ryc. 4. Wpływ ATO na lokalizację cykliny A w linii 
komórkowej Jurkat 
Komórki traktowane 1, 3 and 5 µM ATO i wybarwione na 
obecność cykliny A (A,B,C,D). Jądra komórkowe 
wybarwione za pomocą DAPI (A',B',C',D'). Strzałki 
wskazują komórki z cytoplazmatyczną ekspresją cykliny A. 










Fig. 5. Image-based cytometry analysis of apoptosis, necrosis 
and cell viability – annexin V/propidium iodide (PI) assay 
A: The percentage of viable, early apoptotic, late apoptotic, 
and necrotic cells. Columns – median percentage of cells. 
Asterisks denote statistical significance as compared to 
control cells (p<0.05). Results are representative of three 
independent experiments. B: Representative dot plots of 
annexin V/PI-stained cells for each of the ATO doses used.  
Ryc. 5. Analiza liczby komórek żywych, apoptotycznych i 
nekrotycznch metodą barwienia aneksyna V/jodek propidyny 
A: Odsetek komórek żywych, wczesnoapoptotycznych, 
późnoapoptotycznych oraz nekrotycznych. Kolumny - średni 
odsetek komórek. Gwiazdki wskazują istotne statystycznie 
różnice w stosunku do komórek kontrolnych (p<0.05). 
Wyniki uzyskano na podstawie trzech niezależnych 
eksperymentów. B: Reprezentatywne wykresy "dot plot" dla 




T-cell acute lymphoblastic leukemia is an 
aggressive hematologic tumor that originates from the 
malignant transformation of T cell progenitors. T-ALL 
is more frequently diagnosed in children and more 
common in males
 
[9]. Arsenic trioxide is a potent 
chemotherapeutic agent against acute promyelocytic 
leukemia (PML)
 
[10-11]. Our in vitro study confirmed 
that ATO exerts cytotoxic effect on Jurkat cell line 
(immortalized line of human T lymphocytes). The 
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observations under transmission electron microscope 
revealed changes in the ultrastructure which are 
characteristic for programmed cell death - apoptosis. 
We observed that Jurkat cells treated with arsenic 
trioxide exhibited several apoptotic hallmarks like cell 
shrinkage, nuclear fragmentation, membrane blebbing 
and chromatin condensation. Moreover, the presence 
of enlarged cells with one big nucleus is typical of 
another cell death type, called mitotic catastrophe. 
Mitotic catastrophe is a chain of events of delayed 
mitosis-linked cell death. This kind of cell death is a 
result of DNA damage or deranged spindle formation 
coupled to the debilitation of different checkpoint 
mechanisms that would normally arrest progression 
into mitosis and hence suppress catastrophic events 
until repair has been achieved
 
[12]. Additionally, we 
observed strong vacuolization after incubation with 
ATO. Such a process may provide a proof that ATO 
can induce autophagy in Jurkat cells. It is consistent 
with several studies that indicate the potency of arsenic 
trioxide in triggering autophagy. Li et al. reported that 
ATO induces autophagy in Burkitt's lymphoma Raji 
cells
 
[13]. It is believed that autophagy plays a dual 
role in cancer cells. The presence of this process as a 
response to chemotherapy is prosurvival and may lead 
to development of drug resistance, but in some cases 
autophagy enhance cytotoxic effect of a drug and leads 
to cell death
 
[14]. However, the  cytoplasmic 
vacuolization observed is not an explicit sign of 
autophagy and it is not possible to determine whether 
autophagy occurs without further, more detailed 
investigations. Nevertheless, collected data allow us to 
assume that arsenic trioxide can induce both – 
apoptotic and non-apoptotic death in Jurkat cells. 
These results coincide with previous studies that 
indicated decreased cell viability and increased DNA 
damage in a dose-dependent manner following arsenic 
trioxide treatment
 
[15]. Arsenic trioxide is an effective 
drug against other leukemia cell lines as well. There is 
some evidence for its anticancer activity in cutaneous 
T-cell lymphoma, malignant T- and B-cell lines and 
HTLV-I-associated adult T-cell leukemia
 
[16–18]. 
Besides, studies have shown that arsenic trioxide can 
be applied in non-hematological malignancies. 
Pettersson et al. reported that ATO in dose 1-8 µM was 
highly cytotoxic to small cell lung cancer lines
 
[19]. 
Han et al. confirmed ATO-induced apoptosis in 







[20]. In this study we investigated cyclin A 
expression and localization in ATO-treated Jurkat 
cells. Disturbed expression of key cell cycle regulators 
is characteristic for most cancers cells. Cyclin A plays 
a crucial role in G1/S and G2/M transition. Improper 
expression of cyclin A has been revealed in many 
cancer types, and the prognostic value of cyclin A 
expression varies among different studies. Ahlin et al. 
investigated cyclin A expression in women with breast 
cancer. Samples were obtained from 190 women who 
died from breast cancer as cases and 190 women alive 
at the time. The study suggests that cyclin A could 
predict early relapse and breast cancer death. In this 
report, patients with low cyclin A had longer 
metastases-free survival compared with patients with 
high cyclin A what  is expected from a good 
proliferative marker. Moreover, survival after 
diagnosis was longer for patients with low cyclin A 
compared with high cyclin A [21]. It has been proven 
that ATO can deplete expression of cyclin A in 
different cell lines
 
[22-23]. In the current study we 
observed a decrease in cyclin A expression after ATO 
treatment. Jun et al. reported that Jurkat cells treated 
with 17-alpha-estradiol showed decreased level of cell 
cycle regulatory proteins, cyclin A, E and cdk4. The 
authors suggest that the 17α-E2-mediated down-
regulation of the protein levels of cdk4, cyclin A, and 
cyclin E, which led to a decrease in the level of hyper 
phosphorylated Rb, might result from the accumulation 
of cells at the M phase. In the cells arrested in G2/M 
apoptosis were induced through the mitochondrial 
cytochrome c-dependent activation of caspase cascade 
and subsequent PARP cleavage, which was negatively 
regulated by Bcl-2
 
[24]. It is be possible that 
mechanism of ATO action involves this pathway. 
Targeted changes in the expression profile of cell 
cycle-related proteins seem to be an effective strategy 
against Jurkat cancer cells. For example Yao et al. 
showed that nonylphenol, activated cell cycle 
inhibitors p21 and p53 and downregulated cyclin A 
expression in Jurkat cells [25]. The majority of cyclin 
A molecules locates in the nucleus. Transport of cyclin 
A from the nucleus to the cytoplasm has been proven, 
but details of the process are unclear. Cyclin A transfer 
from the nucleus requires binding with its CDK2 
partner. In the cytoplasm cyclin A is attached to the 
endoplasmic reticulum by SCAPER protein (S phase 
cyclin A-associated protein residing in the endoplasmic 
reticulum) 
 
[26-27]. It shall be deemed that the function 
of cyclin A is connected with its localization and 
cytoplasmic pool of this protein is involved in 
apoptotic pathway
 
[7]. However, in our study the 
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symptoms of extensive cyclin A shuttling between the 
nucleus and the cytoplasm were not observed.  
In conclusion, we confirmed cytotoxic effect of 
arsenic trioxide on the Jurkat cell line. Our 
observations suggest that arsenic trioxide can induce 
several types of cell death.  We described changes in 
the ultrastructure and morphology of Jurkat cells after 
ATO treatment. At the same time, we confirmed that 
arsenic trioxide could deplete expression of cyclin A, 
but without alterations in its localization, which is 
mainly nuclear. The link between apoptosis and cyclin 
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